Shukra Pharmaceuticals lists on NSE main board from 14 Aug 2026

Capital Market Events View source PDF Explain this filing

SHUKRAPHAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

—Next day

—

prior close

₹40.31

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%—

Pharmaceuticals peers, median of 167sector-0.4%—

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+0.0

15m

+0.6

30m

+0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

—+0.1—-0.4—

Next day

—+0.2—-0.4—

—+0.6—-0.5—

—-0.0—-1.4—

—+0.5—-0.9—

—+0.8—-0.4—

—+0.6—-0.9—

15d

—+1.3—+0.0—

—-1.4—-0.1—

—-0.6—-2.8—

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Shukra Pharmaceuticals Limited has been listed on the Main Board of NSE from 14 Aug 2026 under the trading symbol SHUKRAPHAR with ISIN INE551C01044. Shares will continue to trade on BSE (scrip code 531351). The base reference price for NSE trading was set using the BSE closing price of 13 Aug 2026. The company says dual listing is aimed at boosting liquidity, widening the investor base, and increasing stakeholder value.

Likely market impact

Dual listing on NSE may improve liquidity and visibility, potentially attracting more retail and institutional investors to the stock.